close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

83.73 +3.80 (+4.75%)
Streaming Delayed Price Updated: 3:24 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Investment Advisor Trims Position in Financial Stock, According to Latest SEC Filing ↗
QCR Holdings, Inc. delivers commercial banking and asset management services to Midwest markets through a multi-bank structure. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Sells CHEF Shares Worth $8.9 Million, According to Latest SEC Filing ↗
Specializing in premium food products, The Chefs' Warehouse serves top restaurants and hospitality clients across North America. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
Globus Medical Inc - A (NYSE:GMED) Passes Navellier's Little Book Screen ↗
Via Chartmill
News headline image
5 Must-Read Analyst Questions From Globus Medical’s Q1 Earnings Call
Globus Medical’s first quarter delivered results ahead of Wall Street’s expectations, but the market reacted negatively, with shares declining over 5%. Manag... 
Via StockStory
Topics Earnings Economy
Globus Medical Inc - A (NYSE:GMED) Screens as a Top-Tier Quality Growth Stock on the Caviar Cruise Investment Model ↗
Via Chartmill
Globus Medical (NYSE:GMED) Delivers Massive Q1 Beat, Guides EPS Higher ↗
Via Chartmill
News headline image
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million ↗
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets. 
Via The Motley Fool
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
Globus Medical Q1 Earnings Call Highlights ↗
Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and... 
Via MarketBeat
Topics Earnings
Globus Medical Inc - A (NYSE:GMED) Fits the Affordable Growth Profile ↗
Via Chartmill
Globus Medical Inc - A (NYSE:GMED) Scores High Growth Momentum and Technical Setup Ratings ↗
Via Chartmill
Globus Medical Inc (NYSE:GMED): A Prime Affordable Growth Stock with Strong Fundamentals ↗
Via Chartmill
Globus Medical Inc. (NYSE:GMED) Presents a Compelling Mix of Strong Fundamentals and Technical Setup ↗
Via Chartmill
Globus Medical Inc (NYSE:GMED): A GARP Stock with Strong Growth and a Reasonable Price ↗
Via Chartmill
News headline image
GMED Q1 Deep Dive: Margin Expansion and Strategy Shift Amid Market Share Gains
Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q1 CY2026, with sales up 27% year on year to $759.9 million. The ... 
Via StockStory
Topics Economy
News headline image
Globus Medical (GMED) Q1 2026 Earnings Transcript ↗
Globus Medical (GMED) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Globus Medical’s (NYSE:GMED) Q1 CY2026: Beats On Revenue
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 27% year on year to $759.9 million. The... 
Via StockStory
News headline image
Globus Medical (GMED) Reports Q1: Everything You Need To Know Ahead Of Earnings
Medical device company Globus Medical (NYSE:GMED) will be reporting earnings this Thursday afternoon. Here’s what you need to know. Globus Medical beat analy... 
Via StockStory
Globus Medical Inc (NYSE:GMED) Beats Q4 Estimates and Raises 2026 EPS Guidance ↗
Via Chartmill
News headline image
Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices &... 
Via StockStory
News headline image
2 Cash-Heavy Stocks with Exciting Potential and 1 We Turn Down
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
2 Reasons to Like GMED and 1 to Stay Skeptical
What a fantastic six months it’s been for Globus Medical. Shares of the company have skyrocketed 62.5%, hitting $94.80. This was partly thanks to its solid q... 
Via StockStory
News headline image
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Is Stagflation Creeping Into the Picture? ↗
GDP data shows an economy that slowed to a crawl in the fourth quarter of 2025 as inflation picked up. 
Via The Motley Fool
Topics Economy Stocks World Trade
News headline image
Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases. 
Via The Motley Fool
News headline image
2 Growth Stocks to Stash and 1 We Turn Down
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
Topics Economy
News headline image
3 Healthcare Stocks to Target This Week
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today